Compare Moderna, Inc. (MRNA) vs Ulta Beauty Inc (ULTA) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

ULTA Beauty trades at $548.66, down 2.92% on the day, with strong technical momentum indicated by bullish moving averages and key support at $542. Fundamentally, the company maintains robust profitability with 39.33% gross margins and 47.45% ROE, though recent earnings showed mixed results with a Q4 miss. Revenue growth has been consistent, reaching $11.3B in 2025, while analyst sentiment remains positive with 56.53% buy ratings.

The outlook for ULTA remains favorable with a consensus price target of $618.29 offering 12.7% upside potential. Key opportunities include omnichannel expansion and digital growth initiatives, while risks involve margin pressure from rising costs and competitive retail landscape. Institutional ownership trends show continued confidence with recent position increases by major funds.